- Report
- September 2026
- 180 Pages
Global
From €3228EUR$3,545USD£2,769GBP
€3586EUR$3,939USD£3,077GBP
- Report
- September 2026
- 187 Pages
Global
From €3228EUR$3,545USD£2,769GBP
€3586EUR$3,939USD£3,077GBP
- Report
- September 2026
- 184 Pages
Global
From €3228EUR$3,545USD£2,769GBP
€3586EUR$3,939USD£3,077GBP
- Report
- September 2026
- 198 Pages
Global
From €3228EUR$3,545USD£2,769GBP
€3586EUR$3,939USD£3,077GBP
- Report
- September 2026
- 371 Pages
Global
From €5326EUR$5,850USD£4,569GBP
- Report
- February 2026
- 250 Pages
Global
From €4088EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4088EUR$4,490USD£3,507GBP
- Report
- August 2025
- 192 Pages
Global
From €3228EUR$3,545USD£2,769GBP
€3586EUR$3,939USD£3,077GBP
- Report
- March 2024
- 118 Pages
Global
From €4097EUR$4,500USD£3,515GBP
- Report
- January 2025
- 82 Pages
Saudi Arabia
From €3187EUR$3,500USD£2,734GBP
- Report
- May 2024
- 134 Pages
Global
From €2731EUR$2,999USD£2,342GBP
€3641EUR$3,999USD£3,123GBP
- Report
- September 2026
- 50 Pages
Global
From €2413EUR$2,650USD£2,070GBP
- Report
- September 2026
- 50 Pages
Global
From €2413EUR$2,650USD£2,070GBP
Raltegravir is an antiretroviral drug used to treat HIV infection. It is a member of the integrase inhibitor class of drugs, which work by blocking the action of the HIV enzyme integrase, preventing the virus from replicating. Raltegravir is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of contracting the virus.
Raltegravir is a widely used drug in the infectious diseases drugs market. It is used in combination with other antiretroviral drugs to treat HIV infection, and is also used to prevent HIV infection in people who are at high risk of contracting the virus. It is generally well tolerated and has few side effects.
Some companies in the Raltegravir market include Merck & Co., Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, and ViiV Healthcare. Show Less Read more
